1
|
Garcia JA and Rini BI: Recent progress in
the management of advanced renal cell carcinoma. CA Cancer J Clin.
57:112–125. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Park MA, Hamed HA, Mitchell C, et al: A
serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal
carcinoma cells and promotes toxicity of agents that increase ROS
and ceramide levels. Mol Pharmacol. 79:360–380. 2011. View Article : Google Scholar
|
3
|
Sunela KL, Kataja MJ, Lehtinen ET, et al:
Prognostic factors and long-term survival in renal cell cancer
patients. Scand J Urol Nephrol. 43:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Jiang G, Zhang L, Xin Y, et al:
Conditionally replicating adenoviruses carrying mda-7/IL-24 for
cancer therapy. Acta Oncol. 51:285–292. 2012. View Article : Google Scholar
|
5
|
Emdad L, Lebedeva IV, Su ZZ, et al:
Historical perspective and recent insights into our understanding
of the molecular and biochemical basis of the antitumor properties
of mda-7/IL-24. Cancer Biol Ther. 8:391–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Colozza M, Sidoni A and Piccart-Gebhart M:
Value of Ki67 in breast cancer: the debate is still open. Lancet
Oncol. 11:414–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Pei DS, Qian GW, Tian H, et al: Analysis
of human Ki-67 gene promoter and identification of the Sp1 binding
sites for Ki-67 transcription. Tumour Biol. 33:257–266. 2012.
View Article : Google Scholar
|
8
|
Zhao L, Gu J, Dong A, et al: Potent
antitumor activity of oncolytic adenovirus expressing mda-7/IL-24
for colorectal cancer. Hum Gene Ther. 16:845–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Liu J, Fang L, Cheng Q, et al: Effects of
G250 promoter controlled conditionally replicative adenovirus
expressing Ki67-siRNA on renal cancer cell. Cancer Sci.
103:1880–1888. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jiang G, Jiang AJ, Cheng Q, et al: A
dual-regulated oncolytic adenovirus expressing interleukin-24
sensitizes melanoma cells to temozolomide via the induction of
apoptosis. Tumour Biol. 34:1263–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wang MJ, Pei DS, Qian GW, et al: p53
regulates Ki-67 promoter activity through p53- and Sp1-dependent
manner in HeLa cells. Tumour Biol. 32:905–912. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Geoerger B, Grill J, Opolon P, et al:
Potentiation of radiation therapy by the oncolytic adenovirus
dl1520 (ONYX-015) in human malignant glioma xenografts. Br J
Cancer. 89:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
13
|
Freytag SO, Barton KN, Brown SL, et al:
Replication-competent adenovirus-mediated suicide gene therapy with
radiation in a preclinical model of pancreatic cancer. Mol Ther.
15:1600–1606. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nandi S, Ulasov IV, Tyler MA, et al:
Low-dose radiation enhances survivin-mediated virotherapy against
malignant glioma stem cells. Cancer Res. 68:5778–5784. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Kuroda S, Fujiwara T, Shirakawa Y, et al:
Telomerase-dependent oncolytic adenovirus sensitizes human cancer
cells to ionizing radiation via inhibition of DNA repair machinery.
Cancer Res. 70:9339–9348. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yu de B, Zhong SY, Yang M, et al: Potent
antitumor activity of double-regulated oncolytic
adenovirus-mediated ST13 for colorectal cancer. Cancer Sci.
100:678–683. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Bhutia SK, Das SK, Azab B, et al:
Targeting breast cancer-initiating/stem cells with melanoma
differentiation-associated gene-7/interleukin-24. Int J Cancer.
133:2726–2736. 2013.PubMed/NCBI
|
18
|
Eulitt PJ, Park MA, Hossein H, et al:
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by
inhibiting multiple protective signaling pathways using sorafenib
and by Ad.5/3 gene delivery. Cancer Biol Ther. 10:1290–1305. 2010.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Park MA, Walker T, Martin AP, et al:
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells
occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer
Ther. 8:1280–1291. 2009. View Article : Google Scholar : PubMed/NCBI
|